JPRN-UMIN000052526招募中Unknown
A biomarker study using tumor-infiltrating lymphocytes in patienst with biliary tract cancer - A biomarker study in biliary tract cancer
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. The sample volume does not remain 2. Under 20 years of age at the time of consent
研究者
相似试验
暂停
不适用
A Biomarker Study Using Tumor-infiltrating Regulatory T Cells to Predict the Efficacy to Immune Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer and Malignant Melanomaon-Small Cell Lung Cancer or Malignant MelanomaJPRN-UMIN000044535Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Hematology, Oncology and Respiratory Medicine130
已完成
不适用
tudy on Biomarkers Using Circulating Tumor Cells When Administering Osimertinib in Patients with EGFR Mutation-positive Lung CancerJPRN-UMIN000032055Toho University50
已完成
不适用
Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung CancerNon-small Cell Lung CarcinomaNCT02848872Duke University25
进行中（未招募）
1 期
A Study of Pembrolizumab Combination Therapy for Advanced Non-Small Cell Lung CancerEUCTR2017-003134-85-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.318
进行中（未招募）
1 期
A Study of Pembrolizumab Combination Therapy for Advanced Non-Small Cell Lung CancerTreatment of advanced NSCLCMedDRA version: 20.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003134-85-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.192